Response to cisplatin in a metastatic triple-negative breast cancer patient

Abstract

Triple-negative breast cancers (TNBCs) are aggressive tumors with a high risk of visceral metastasis and poor prognosis. Here, we report a case of a 57-year-old postmenopausal female with gBRCA1-positive metastatic breast cancer. She was treated for endometrioid type, Stage IB Grade 2 endometrial carcinoma with pelvic external beam radiation in 2014. In 2016, she developed Stage I TNBC for which she underwent BCS followed by chemotherapy with anthracycline and taxanes. She also received accelerated partial breast irradiation. In 2019, she developed brain and lung metastasis. For the brain disease, she underwent gross total excision followed by whole-brain radiotherapy (WBRT). For the lung lesion, she received stereotactic body radiotherapy. Subsequently, she developed extensive metastases which were treated with cisplatin and vinorelbine chemotherapy and had a complete response. Within 5 months, she developed rapid progression of the disease in brain, lungs, and right adrenal. She was treated with palliative WBRT, but she died of progressive disease within the next 2 months.

Keywords

• cisplatin
• metastatic breast cancer
• triple negative